Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review Export

@article{citeulike:1182686, abstract = {Summary Positron-emission tomography (PET) with 18-fluorodeoxyglucose has a role in the diagnosis and staging of lung cancer, but is also appealing for assessment of prognosis and treatment. A systematic search of the published work shows good evidence that [18F]FDG uptake on PET has independent prognostic value in newly diagnosed nonsmall- cell lung cancer. PET is a sensitive method of measuring the biological effects of anticancer therapy, but until better standardisation and large-scale experience is available, it should only be used for additional assessments of early response in clinical trials. Further studies are needed to define the role of [18F]FDG-PET in restaging after induction therapy in multimodality approaches for locally advanced lung cancer. The assessment of prognosis by [18F]FDG-PET is less substantiated in treated lung cancer than in newly diagnosed patients. Good prospective evidence documents the effectiveness of [18F]FDG-PET over CT in the correct identification of recurrent lung cancer.}, author = {Vansteenkiste, Johan and Fischer, Barbara M. and Dooms, Christophe and Mortensen, Jann}, citeulike-article-id = {1182686}, citeulike-linkout-0 = {http://dx.doi.org/10.1016/S1470-2045(04)01564-5}, citeulike-linkout-1 = {http://www.sciencedirect.com/science/article/B6W85-4D67K24-M/2/d8b49d3f04e702622c51eff599d9dc95}, comment = {paper reference}, doi = {10.1016/S1470-2045(04)01564-5}, journal = {The Lancet Oncology}, keywords = {chemotherapy, lung-cancer, paper1, pet, treatment-response}, month = {September}, number = {9}, pages = {531--540}, posted-at = {2007-03-24 13:27:34}, priority = {2}, title = {Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review}, url = {http://dx.doi.org/10.1016/S1470-2045(04)01564-5}, volume = {5}, year = {2004} }

TY - JOUR ID - citeulike:1182686 L3 - citeulike-article-id:1182686 N2 - Summary Positron-emission tomography (PET) with 18-fluorodeoxyglucose has a role in the diagnosis and staging of lung cancer, but is also appealing for assessment of prognosis and treatment. A systematic search of the published work shows good evidence that [18F]FDG uptake on PET has independent prognostic value in newly diagnosed nonsmall- cell lung cancer. PET is a sensitive method of measuring the biological effects of anticancer therapy, but until better standardisation and large-scale experience is available, it should only be used for additional assessments of early response in clinical trials. Further studies are needed to define the role of [18F]FDG-PET in restaging after induction therapy in multimodality approaches for locally advanced lung cancer. The assessment of prognosis by [18F]FDG-PET is less substantiated in treated lung cancer than in newly diagnosed patients. Good prospective evidence documents the effectiveness of [18F]FDG-PET over CT in the correct identification of recurrent lung cancer. IS - 9 JF - The Lancet Oncology EP - 540 TI - Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review VL - 5 SP - 531 KW - chemotherapy KW - lung-cancer KW - paper1 KW - pet KW - treatment-response N1 - paper reference AU - Vansteenkiste, Johan AU - Fischer, Barbara AU - Dooms, Christophe AU - Mortensen, Jann PY - 2004/09// UR - http://dx.doi.org/10.1016/S1470-2045(04)01564-5 ER -